SGLT1/2 Inhibitor Sotagliflozin ' Encouraging ' in Type 1 Diabetes SGLT1/2 Inhibitor Sotagliflozin ' Encouraging ' in Type 1 Diabetes

The investigational, oral agent sotagliflozin, a first-in-class, oral dual inhibitor of both SGLT1 and SGLT2, is in phase 3 trials in type 1 diabetes; results are promising but there are some caveats.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news